This study presents the findings of a national survey of physicians about their knowledge of biosimilar biological products as well as the impact of biological product naming conventions on prescriber choice.
Related Products
Office of Science and Data Policy (SDP)
The Office of Science and Data Policy is the departmental focal point for policy research, analysis, evaluation, and coordination of department-wide public health science policy and data policy activities and issues. The Office provides authoritative advice and analytical support to the ASPE and departmental leadership on public health science policy and data policy issues and initiatives, coordinates science and data policy issues of interagency scope within HHS, and manages interagency initiatives in science policy and data policy. The Office works closely with staff from across the Department on strategic plan development and implementation efforts. The Offices also carries out a program of policy research, analysis, evaluation, and data development in these issues.
The Office of Science and Data Policy includes several components:
- Division of Science and Public Health Policy
- Division of Evidence, Evaluation and Data Policy
- Division of Strategic Planning
Topic Areas:
- HHS Data Council
- Regulatory Impact Analysis
- Strategic Planning
- Information Quality Guidelines
- Prevention and wellness
- Public health systems and functions
- Food safety and nutrition
- Drugs and devices
- Tobacco control and prevention
- Biomedical research and development
- Economic analysis
- Emergency preparedness, response, and recovery
- Data and statistical policy
- Health disparities and vulnerable populations
- Health information technology
- Microsimulation
- Privacy policy
Reports
Displaying 61 - 70 of 157. 10 per page. Page 7.
Advanced SearchPhysician Understanding and Willingness to Prescribe Biosimilars: Findings from a US National Survey
Department of Health & Human Services Evaluation Policy
This is an evaluation policy for the Department of Health and Human Services (HHS), required by the Foundations for Evidence-based Policymaking Act of 2018 (Evidence Act). ASPE convened a group of agency representatives from across HHS operating and staff divisions to develop the policy.
Department of Health & Human Services FY 2022 Evaluation Plan
As part of the Evidence Act, HHS is required to submit “an evaluation plan describing activities the agency plans to conduct pursuant to [its evidence-building plan].” Nine operating divisions within HHS and one staff division developed evaluation plans and included information on priority questions being examined by the agencies as well as data, methods, and challenges to addressing those ques
To Big Data or Not: Determining the Use of Big Data
The purpose of this research project was to provide the Office of Science and Data Policy at ASPE with some informed observations concerning the use of new data sources and data management strategies in policy research, evaluation, and decision-making at the federal level. A secondary goal was to identify successful training models in data science for the federal workforce.
2018 HHS Data Strategy: Enhancing the HHS Evidence-Based Portfolio
The 2018 HHS Data Strategy focuses on improving the Department’s capacity to develop statistical evidence to support policymaking and program evaluation over the next six to eight years.
Using Evidence to Drive Decision-Making in Government
This report presents the findings from the Policy Analysis and Decision-Making Capacity project, funded by the Office of Science and Data Policy within the Office of the Assistant Secretary for Planning and Evaluation at the U.S. Department of Health and Human Services.
Economic Incentives for the Development of Rapid Point-of-Care (POC) Diagnostic Devices for C.Difficile, Carbapenem-Resistant Enterobacteriaceae (CRE), and Neisseria Gonorrhoeae
Antibacterial resistance is responsible for excess morbidity, mortality, and medical costs around the globe. Estimates vary widely, but the economic cost of antibacterial resistance in the United States could be as high as $20 billion and $35 billion a year in excess direct healthcare costs and lost productivity costs, respectively. CDC’s most recent report on U.S.
Examining Consumer Responses to Calorie Information on Restaurant Menus in a Discrete Choice Experiment
The 2014 U.S. Food and Drug Administration (FDA) final rule, “Food Labeling: Nutrition Labeling of Standard Menu Items in Restaurants and Similar Retail Food Establishments,” requires information on the calorie content of food items to be clearly displayed on menus.
Costs and Benefits of Selected Policy Tools to Promote Drug Development
The development of new drugs and biologics is critical to ensuring that the U.S. population continues to enjoy improvements in quality and length of life.
Estimating Medical Costs for Regulatory Benefit-Cost Analysis: Conceptual Framework and Best Practices
The U.S. Department of Health and Human Services (HHS) is required to assess the benefits and costs of its major regulations prior to promulgation. To support these assessments, in 2016 HHS issued its Guidelines for Regulatory Impact Analyses, developed under the leadership of its Office of the Assistant Secretary for Planning and Evaluation and its Department-wide Analytics Team.